Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Rated “Moderate Buy” by Sell-Side Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $44.25.

STOK has been the topic of several research reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Stoke Therapeutics in a research report on Thursday, September 10th. Chardan Capital reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Guggenheim reiterated a “buy” rating and issued a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Finally, Canaccord Genuity Group cut their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th.

Insider Activity

In related news, General Counsel Jonathan Allan sold 2,861 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $91,637.83. Following the sale, the general counsel directly owned 21,225 shares in the company, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total value of $27,494.16. Following the transaction, the insider directly owned 19,059 shares in the company, valued at $498,583.44. This trade represents a 5.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 34,594 shares of company stock worth $1,069,305. 9.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its position in Stoke Therapeutics by 22.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after purchasing an additional 359 shares during the last quarter. First Trust Advisors LP lifted its position in Stoke Therapeutics by 0.5% in the first quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock worth $5,322,000 after purchasing an additional 780 shares during the period. Quantbot Technologies LP acquired a new stake in Stoke Therapeutics in the second quarter worth approximately $34,000. KBC Group NV bought a new position in Stoke Therapeutics during the 1st quarter valued at $36,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Stoke Therapeutics by 195.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock valued at $60,000 after purchasing an additional 1,215 shares in the last quarter.

Stoke Therapeutics Price Performance

STOK opened at $25.70 on Friday. Stoke Therapeutics has a 1 year low of $20.32 and a 1 year high of $40.22. The company’s 50 day simple moving average is $28.11 and its 200 day simple moving average is $30.35.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to analysts’ expectations of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. As a group, sell-side analysts anticipate that Stoke Therapeutics will post -3.52 earnings per share for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders.

Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.